Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease

J. W. Baddley1, J. R. Perfect2, R. A. Oster3, R. A. Larsen4, G. A. Pankey5, H. Henderson6, D. W. Haas7, C. A. Kauffman8, R. Patel9, A. K. Zaas2, P. G. Pappas1
1Division of Infectious Diseases and International Health, Department of Medicine, University of Alabama at Birmingham, Birmingham, USA
2Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, USA
3Biostatistics and Bioinformatics Unit, Department of Medicine, University of Alabama at Birmingham, Birmingham, USA
4Division of Infectious Diseases, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, USA
5Division of Infectious Diseases, Department of Medicine, Ochsner Clinic, New Orleans, USA
6Division of Infectious Diseases, Department of Medicine, University of Mississippi Medical Center, Jackson, USA
7Department of Medicine, Vanderbilt University Medical Center, Nashville, USA.
8Department of Medicine, University of Michigan and Veterans Affairs, Ann Arbor Healthcare System, Ann Arbor, USA
9Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, USA

Tóm tắt

Cryptococcus neoformans is an uncommonly recognized cause of pneumonia in HIV-negative patients. Because of its propensity to disseminate to the meninges and other sites, a lumbar puncture is recommended for patients with pulmonary cryptococcosis, regardless of other risk factors. This study explored clinical and laboratory features to help predict which patients had pulmonary disease alone versus those who had pulmonary plus extrapulmonary disease. A retrospective chart review at 15 medical centers was performed from 1990 to 2000 of all HIV-negative patients who had pulmonary cryptococcosis. Demographic, clinical, radiographic, and laboratory features were evaluated to determine factors that differentiated those patients who had extrapulmonary disease. Among 166 patients who had pulmonary cryptococcosis, 122 had pulmonary infection only and 44 had pulmonary plus extrapulmonary (disseminated) disease. A negative serum cryptococcal antigen titer was more common in patients with pulmonary disease alone (p < 0.01). Multivariate analysis demonstrated that patients who had disseminated disease were more likely than those who only had pulmonary disease to have cirrhosis (p = 0.049), headache (p < 0.001), weight loss (p = 0.003), fever (p = 0.035), altered mental status (p < 0.001), and to be receiving high-dose corticosteroids (p = 0.008). In this large cohort of HIV-negative patients with pulmonary cryptococcosis, there were easily distinguished clinical and laboratory features among patients with pulmonary disease alone versus those with pulmonary plus extrapulmonary disease. These findings may be helpful in the evaluation of HIV-negative patients with pulmonary cryptococcosis with regard to the need for lumbar puncture or to search for disseminated disease.

Tài liệu tham khảo

Levitz SM (1991) The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 13(6):1163–1169 Chayakulkeeree M, Perfect JR (2006) Cryptococcosis. Infect Dis clin North Am 20(3):507–544 v–vi Pappas PG, Perfect JR, Cloud GA et al (2001) Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 33(5):690–699 Dromer F, Mathoulin S, Dupont B, Brugiere O, Letenneur L (1996) Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. Clin Infect Dis 22 [Suppl 2]:S154–S160 Saag MS, Graybill RJ, Larsen RA et al (2000) Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 30(4):710–718 Saag MS, Powderly WG, Cloud GA et al (1992) Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 326(2):83–89 Van der Horst CM, Saag MS, Cloud GA et al (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 337(1):15–21 Dismukes WE (1993) Management of cryptococcosis. Clin Infect Dis 17 [Suppl 2]:S507–S512 Bennett JE, Dismukes WE, Duma RJ et al (1979) A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal [sic] meningitis. N Engl J Med 301(3):126–131 Dismukes WE, Cloud G, Gallis HA et al (1987) Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 317(6):334–341 Kerkering TM, Duma RJ, Shadomy S (1981) The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med 94(5):611–616 Aberg JA, Mundy LM, Powderly WG (1999) Pulmonary cryptococcosis in patients without HIV infection. Chest 115(3):734–740 Aberg JA (2003) Pulmonary cryptococcosis in normal hosts: treat or observe? Chest 124(6):2049–2051 Woodring JH, Ciporkin G, Lee C, Worm B, Woolley S (1996) Pulmonary cryptococcosis. Semin Roentgenol 31(1):67–75 Nadrous HF, Antonios VS, Terrell CL, Ryu JH (2003) Pulmonary cryptococcosis in nonimmunocompromised patients. Chest 124(6):2143–2147 Kontoyiannis DP, Peitsch WK, Reddy BT et al (2001) Cryptococcosis in patients with cancer. Clin Infect Dis 32(11):E145–E150 Ascioglu S, Rex JH, de Pauw B et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34(1):7–14 Larsen RA, Leal MA, Chan LS (1990) Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 113(3):183–187 Bicanic T, Meintjes G, Wood R et al (2007) Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 45(1):76–80 Brouwer AE, Rajanuwong A, Chierakul W et al (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363(9423):1764–1767 Perfect JR (1989) Cryptococcosis. Infect Dis Clin North Am 3(1):77–102 Singh N, Husain S, De Vera M, Gayowski T, Cacciarelli TV (2004) Cryptococcus neoformans infection in patients with cirrhosis, including liver transplant candidates. Medicine 83(3):188–192 Park WB, Choe YJ, Lee KD et al (2006) Spontaneous cryptococcal peritonitis in patients with liver cirrhosis. Am J Med 119(2):169–171 El-Serag HB, Anand B, Richardson P, Rabeneck L (2003) Association between hepatitis C infection and other infectious diseases: a case for targeted screening? Am J Gastroenterol 98(1):167–174 Robinson PA, Bauer M, Leal MA et al (1999) Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 28(1):82–92 Singh N, Alexander BD, Lortholary O et al (2008) Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis 46(2):e12–e18 Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O (2007) Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 4(2):e21 Vilchez RA, Irish W, Lacomis J, Costello P, Fung J, Kusne S (2001) The clinical epidemiology of pulmonary cryptococcosis in non-AIDS patients at a tertiary care medical center. Medicine 80(5):308–312 Vilchez RA, Linden P, Lacomis J, Costello P, Fung J, Kusne S (2001) Acute respiratory failure associated with pulmonary cryptococcosis in non-aids patients. Chest 119(6):1865–1869 Chang WC, Tzao C, Hsu HH et al (2006) Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest 129(2):333–340